Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Hiromasa Horimoto"'
Autor:
Masatsugu Ohara, Takuya Sho, Michio Nakamura, Hiromasa Horimoto, Koji Ogawa, Naoki Kawagishi, Goki Suda, Takaaki Izumi, Takashi Meguro, Kenichi Morikawa, Mitsuru Nakanishi, Jun Ito, Naoya Sakamoto, Machiko Umemura, Masato Nakai, Makoto Chuma, Atsushi Nagasaka, Yoshiya Yamamoto
Publikováno v:
Drugs in R&D
Background and aims: Sorafenib is the first molecular targeted drug approved for the treatment of advanced hepatocellular carcinoma (HCC) and is a potent small molecule inhibitor of multiple kinases. Combination therapy with sorafenib and other cytot
Autor:
Mitsuteru Natsuizaka, Miki Tateyama, Hiromasa Horimoto, Keisuke Shinada, Seiji Tsunematsu, Goki Suda, Atsushi Nagasaka, Mineo Kudo, Machiko Umemura, Takaaki Izumi, Katsumi Terashita, Koji Ogawa, Takuya Sho, Ken Furuya, Yoko Tsukuda, Fumiyuki Sato, Masato Nakai, Naoya Sakamoto, Jun Konno, Megumi Kimura, Yoshiya Yamamoto, Kazushi Yamasaki, Tomoe Kobayashi, Kenichi Morikawa
Publikováno v:
Journal of gastroenterology. 51(7):733-740
Background: HCV infection in chronic hemodialysis patients is high, has a poor prognosis and high risk of renal graft failure, and requires nosocomial infection control measures. However, options of anti-HCV therapy in such patients are limited and u
Autor:
Jason Matthews, Masahiro Asaka, Hiromasa Horimoto, Masayoshi Dazai, Debbie Bott, Akinori Takaoka, Takeshi Kameyama, Taisho Yamada, Hiroaki Yamato, Ayato Takada, Tania H. Watts, Angela C. Zhou, Hiroshi Kida, Sumio Hayakawa, David Hutin
Publikováno v:
Nature Immunology. 17:687-694
Aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that mediates the toxic activity of many environmental xenobiotics. However, its role in innate immune responses during viral infection is not fully understood. Here we demons
Autor:
Goki, Suda, Yoshiya, Yamamoto, Astushi, Nagasaka, Ken, Furuya, Mineo, Kudo, Yoshimichi, Chuganji, Yoko, Tsukuda, Seiji, Tsunematsu, Fumiyuki, Sato, Katsumi, Terasita, Masato, Nakai, Hiromasa, Horimoto, Takuya, Sho, Mitsuteru, Natsuizaka, Kouji, Ogawa, Shunsuke, Ohnishi, Makoto, Chuma, Yasuyuki, Fujita, Riichiro, Abe, Miki, Taniguchi, Mina, Nakagawa, Yasuhiro, Asahina, Naoya, Sakamoto
Publikováno v:
Hepatology research. 45(8):837-845
Aim: Telaprevir-based therapy for chronic hepatitis C patients is effective; however, the high prevalence of dermatological reactions is an outstanding issue. The mechanism and characteristics of such adverse reactions are unclear; moreover, predicti
Autor:
Yoko Tsukuda, Ken Furuya, Masato Nakai, Yoshimichi Chuganji, Yasuhiro Asahina, Fumiyuki Sato, Astushi Nagasaka, Mitsuteru Natsuizaka, Shunsuke Ohnishi, Takuya Sho, Seiji Tsunematsu, Goki Suda, Hiromasa Horimoto, Miki Taniguchi, Yoshiya Yamamoto, Riichiro Abe, Katsumi Terasita, Naoya Sakamoto, Makoto Chuma, Kouji Ogawa, Mina Nakagawa, Yasuyuki Fujita, Mineo Kudo
Publikováno v:
Hepatology Research. 45:837-845
Aim Telaprevir-based therapy for chronic hepatitis C patients is effective; however, the high prevalence of dermatological reactions is an outstanding issue. The mechanism and characteristics of such adverse reactions are unclear; moreover, predictiv
Autor:
Mitsuteru Natsuizaka, Tomoe Kobayashi, Fumiyuki Sato, Hiromi Fujita, Katsumi Terashita, Yoko Tsukuda, Naoya Sakamoto, Takuya Sho, Satoshi Hashino, Seiji Tsunematsu, Mitsuru Nakanishi, Masato Nakai, Makoto Chuma, Hiromasa Horimoto, Goki Suda, Noriyuki Otsuka
Publikováno v:
Internal Medicine. 53:2079-2082
Hepatosplenic gamma-delta T-cell lymphoma (HSTCL) is a rare, aggressive subset of peripheral T-cell lymphoma. It has been reported that Epstein-Barr virus (EBV) infection can cause HSTCL; however, such cases are extremely rare, with only a few cases
Autor:
Masato Nakai, Mitsuru Nakanishi, Hiromasa Horimoto, Shuhei Hige, Koji Ogawa, Takuya Sho, Makoto Chuma, Katsumi Terashita, Naoya Sakamoto, Masahiro Asaka, Tomoe Kobayashi
Publikováno v:
Journal of Gastroenterology. 47:1228-1237
An inosine triphosphatase (ITPA) single-nucleotide polymorphism (SNP) is associated with anemia induced by pegylated interferon and ribavirin (RBV) combination therapy in patients with chronic hepatitis C (CHC). However, there are very few reports on
Autor:
Shuhei Hige, Mototsugu Kato, Koji Ogawa, Masato Nakai, Masahiro Asaka, Hiroki Shirato, Hiroshi Taguchi, Hiromasa Horimoto, Takuya Sho, Yusuke Sakuhara, Makoto Chuma, Tomoe Kobayashi, Mitsuru Nakanishi, Daisuke Abo, Katsumi Terashita, Shinichi Shimizu, Yoko Tsukuda, Seiji Tsunematsu, Yoshiya Yamamoto
Publikováno v:
Journal of Gastroenterology and Hepatology. 26:1123-1132
Background and Aim: To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (P
Autor:
Tomoe Kobayashi, Takuya Sho, Masahiro Asaka, Mitsuru Nakanishi, Yoichi Yamamoto, Hiromasa Horimoto, Shigeru Yoshida, Makoto Chuma, Shuhei Hige, Mitsuteru Natsuizaka, Keiko Yamamoto
Publikováno v:
Journal of Clinical Microbiology. 48(12):4487-4494
Lamivudine is the first nucleoside analogue that was shown to have a potent effect on hepatitis B virus (HBV). However, the emergence of mutants resistant or cross-resistant to nucleoside/nucleotide analogues remains a serious problem. Several assays
Autor:
Makoto, Chuma, Hiroshi, Taguchi, Yoshiya, Yamamoto, Shinichi, Shimizu, Mitsuru, Nakanishi, Koji, Ogawa, Takuya, Sho, Hiromasa, Horimoto, Tomoe, Kobayashi, Masato, Nakai, Katsumi, Terashita, Yusuke, Sakuhara, Daisuke, Abo, Yoko, Tsukuda, Seiji, Tsunematsu, Shuhei, Hige, Mototsugu, Kato, Hiroki, Shirato, Masahiro, Asaka
Publikováno v:
Journal of gastroenterology and hepatology. 26(7)
To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT).Twenty HCC pati